Arecor Therapeutics PLC Arecor on Investor Meet Company Platform
April 21 2023 - 2:00AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
21 April 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company Platform
Cambridge, UK, 21 April 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that Sarah Howell, Chief
Executive Officer and Susan Lowther, Chief Financial Officer will
be providing a live presentation relating to the Group's recently
announced results for the year ended 31 December 2022 via the
Investor Meet Company platform, on Wednesday 26 April 2023 at
14.00pm BST.
The presentation is open to all existing and potential
shareholders and will be followed by a Q&A session. Questions
can be submitted ahead of the event through the Investor Meet
Company dashboard until 9am BST on Tuesday 25 April, or at any time
during the live presentation.
To sign up to Investor Meet Company for free and to register for
Arecor's presentation, please visit:
https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor
.
Investors who already follow Arecor on the Investor Meet Company
platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
. For further details please see our website, www.arecor.com
-
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAIMMLTMTMTBFJ
(END) Dow Jones Newswires
April 21, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Sep 2023 to Sep 2024